FTC obtains stipulated TRO blocking Amgen's Horizon acquisition until Sept 15 or court ruling

AMGEN INC

FTC filed complaint May 16, 2023 in N.D. Illinois seeking to enjoin $27.8B acquisition of Horizon Therapeutics.
Stipulated TRO granted May 17, 2023: Amgen and Horizon cannot close deal until Sept 15, 2023 or 2nd business day after court rules on FTC's preliminary injunction request.
Parties agreed to the stipulated TRO to allow court to consider the FTC's request.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.